RegeneRx JV partner gets $7.28 million funding for US development of RGN-259/GBT-201 from Korea

9 March 2015

US biotech firm RegeneRx Biopharmaceuticals (OTC Bulletin Board: RGRX) says it has been notified that its joint venture partner and licensee, South Korea’s G-treeBNT (Kosdaq: 115450) will receive $7.28 million to expand international development of its product candidate, RGN-259 (designated GBT-201).

G-treeBNT will receive a $5.92 million investment from Global Pharmaceutical Industry Development Fund, which was raised in September, 2013 to support selected Korean pharma or bioventure firms developing new drugs for the global market. This specialized fund was created by the Korean Ministry of Health and Welfare and is managed by InterVest which is a leading healthcare venture capital firm in Korea.

G-treeBNT will also receive an additional $1.36 million investment from E&Investment, a Korean venture capital firm. The $7.28 million will be used for development of RGN-259/GBT-201 for dry eye syndrome and neurotrophic keratopathy in the USA through a recently created US joint venture between G-treeBNT and RegeneRx, called ReGenTree LLC.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK